Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2016, Article ID 8408479, 14 pages
http://dx.doi.org/10.1155/2016/8408479
Review Article

Cardiovascular and Hepatic Toxicity of Cocaine: Potential Beneficial Effects of Modulators of Oxidative Stress

1Department of Physiology and Pharmacology “Vittorio Erspamer”, Sapienza University of Rome, Rome, Italy
2Drug Addiction and Clinical Pharmacology Unit, University Hospital Umberto I, Sapienza University of Rome, Rome, Italy
3Sussex Addiction Research and Intervention Centre (SARIC), School of Psychology, University of Sussex, Brighton BN1 9RH, UK

Received 7 August 2015; Revised 19 October 2015; Accepted 1 November 2015

Academic Editor: José L. Quiles

Copyright © 2016 Manuela Graziani et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. O. Firuzi, R. Miri, M. Tavakkoli, and L. Saso, “Antioxidant therapy: current status and future prospects,” Current Medicinal Chemistry, vol. 18, no. 25, pp. 3871–3888, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. L. Saso and O. Firuzi, “Pharmacological applications of antioxidants: lights and shadows,” Current Drug Targets, vol. 15, no. 13, pp. 1177–1199, 2014. View at Publisher · View at Google Scholar
  3. J. D. Uys, P. J. Mulholland, and D. M. Townsend, “Glutathione and redox signaling in substance abuse,” Biomedicine & Pharmacotherapy, vol. 68, no. 6, pp. 799–807, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. A. O. Sordi, F. Pechansky, F. H. P. Kessler et al., “Oxidative stress and BDNF as possible markers for the severity of crack cocaine use in early withdrawal,” Psychopharmacology, vol. 231, no. 20, pp. 4031–4039, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. C. T. D. Antoniazzi, N. Boufleur, C. S. Pase et al., “Tactile stimulation and neonatal isolation affect behavior and oxidative status linked to cocaine administration in young rats,” Behavioural Processes, vol. 103, pp. 297–305, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. T. Cunha-Oliveira, L. Silva, A. M. Silva, A. J. Moreno, C. R. Oliveira, and M. S. Santos, “Acute effects of cocaine, morphine and their combination on bioenergetic function and susceptibility to oxidative stress of rat liver mitochondria,” Life Sciences, vol. 92, no. 24–26, pp. 1157–1164, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. V. Bashkatova, J. Meunier, A. Vanin, and T. Maurice, “Nitric oxide and oxidative stress in the brain of rats exposed in utero to cocaine,” Annals of the New York Academy of Sciences, vol. 1074, pp. 632–642, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. V. Bashkatova, J. Meunier, T. Maurice, and A. Vanin, “Memory impairments and oxidative stress in the hippocampus of in-utero cocaine-exposed rats,” NeuroReport, vol. 16, no. 11, pp. 1217–1221, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. B. G. Devi and A. W. K. Chan, “Cocaine-induced peroxidative stress in rat liver: antioxidant enzymes and mitochondria,” Journal of Pharmacology and Experimental Therapeutics, vol. 279, no. 1, pp. 359–366, 1996. View at Google Scholar · View at Scopus
  10. K. Moore and L. J. Roberts II, “Measurement of lipid peroxidation,” Free Radical Research, vol. 28, no. 6, pp. 659–671, 1998. View at Publisher · View at Google Scholar · View at Scopus
  11. D. L. Coleman, T. F. Ross, and J. L. Naughton, “Myocardial ischemia and infarction related to recreational cocaine use,” Western Journal of Medicine, vol. 136, no. 5, pp. 444–446, 1982. View at Google Scholar · View at Scopus
  12. R. Virmani, M. Robinowitz, J. E. Smialek, and D. F. Smyth, “Cardiovascular effects of cocaine: an autopsy study of 40 patients,” American Heart Journal, vol. 115, no. 5, pp. 1068–1076, 1988. View at Publisher · View at Google Scholar · View at Scopus
  13. R. A. Lange, R. G. Cigarroa, C. W. Yancy Jr. et al., “Cocaine-induced coronary-artery vasoconstriction,” The New England Journal of Medicine, vol. 321, no. 23, pp. 1557–1562, 1989. View at Publisher · View at Google Scholar · View at Scopus
  14. B. G. Schwartz, S. Rezkalla, and R. A. Kloner, “Cardiovascular effects of cocaine,” Circulation, vol. 122, no. 24, pp. 2558–2569, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Maraj, V. M. Figueredo, and D. L. Morris, “Cocaine and the heart,” Clinical Cardiology, vol. 33, no. 5, pp. 264–269, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. R. A. Lange and L. D. Hillis, “Cardiovascular complications of cocaine use,” The New England Journal of Medicine, vol. 345, no. 5, pp. 351–358, 2001. View at Publisher · View at Google Scholar · View at Scopus
  17. J. A. Feldman, S. S. Fish, J. R. Beshansky, J. L. Griffith, R. H. Woolard, and H. P. Selker, “Acute cardiac ischemia in patients with cocaine-associated complaints: results of a multicenter trial,” Annals of Emergency Medicine, vol. 36, no. 5, pp. 469–476, 2000. View at Google Scholar · View at Scopus
  18. J. E. Weber, C. R. Chudnofsky, M. Boczar, E. W. Boyer, M. D. Wilkerson, and J. E. Hollander, “Cocaine-associated chest pain: how common is myocardial infarction?” Academic Emergency Medicine, vol. 7, no. 8, pp. 873–877, 2000. View at Publisher · View at Google Scholar · View at Scopus
  19. P. M. Kanani, P. A. Guse, W. M. Smith, A. Barnett, and E. H. Ellinwood Jr., “Acute deleterious effects of cocaine on cardiac conduction, hemodynamics, and ventricular fibrillation threshold: effects of interaction with a selective dopamine D1 antagonist SCH 39166,” Journal of Cardiovascular Pharmacology, vol. 32, no. 1, pp. 42–48, 1998. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Frustaci, M. A. Russo, E. Morgante et al., “Oxidative myocardial damage in human cocaine-related cardiomyopathy,” Free Radical Biology & Medicine, vol. 17, no. 3, pp. 283–290, 2015. View at Google Scholar
  21. R. J. Henning and Y. Li, “Cocaine produces cardiac hypertrophy by protein kinase C dependent mechanisms,” Journal of Cardiovascular Pharmacology and Therapeutics, vol. 8, no. 2, pp. 149–160, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. M. E. Brickner, J. E. Willard, E. J. Eichhorn, J. Black, and P. A. Grayburn, “Left ventricular hypertrophy associated with chronic cocaine abuse,” Circulation, vol. 84, no. 3, pp. 1130–1135, 1991. View at Publisher · View at Google Scholar · View at Scopus
  23. J. L. Pilgrim, N. Woodford, and O. H. Drummer, “Cocaine in sudden and unexpected death: a review of 49 post-mortem cases,” Forensic Science International, vol. 227, no. 1–3, pp. 52–59, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Darke, S. Kaye, and J. Duflou, “Cocaine-related fatalities in New South Wales, Australia 1993–2002,” Drug and Alcohol Dependence, vol. 77, no. 2, pp. 107–114, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. EMCDDA, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, Portugal, 2014, http://www.emcdda.europa.eu/edr.
  26. J. McCord, H. Jneid, J. E. Hollander et al., “Management of cocaine-associated chest pain and myocardial infarction: a scientific statement from theAmerican Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology,” Circulation, vol. 117, no. 14, pp. 1897–1907, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. N. Gupta, J. B. Washam, S. E. Mountantonakis et al., “Characteristics, management, and outcomes of cocaine-positive patients with acute coronary syndrome (from the National Cardiovascular Data Registry),” American Journal of Cardiology, vol. 113, no. 5, pp. 749–756, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. S. B. Karch, “Cardiac arrest in cocaine users,” The American Journal of Emergency Medicine, vol. 14, no. 1, pp. 79–81, 1996. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Silvanto, S. V. de Noronha, and M. N. Sheppard, “Myocardial infarction with normal coronaries: an autopsy perspective,” Journal of Clinical Pathology, vol. 65, no. 6, pp. 512–516, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. L. Liaudet, B. Calderari, and P. Pacher, “Pathophysiological mechanisms of catecholamine and cocaine-mediated cardiotoxicity,” Heart Failure Reviews, vol. 19, no. 6, pp. 815–824, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. R. V. Stankowski, R. A. Kloner, and S. H. Rezkalla, “Cardiovascular consequences of cocaine use,” Trends in Cardiovascular Medicine, vol. 25, no. 6, pp. 517–526, 2015. View at Publisher · View at Google Scholar
  32. E. Turillazzi, S. Bello, M. Neri, C. Pomara, I. Riezzo, and V. Fineschi, “Cardiovascular effects of cocaine: cellular, ionic and molecular mechanisms,” Current Medicinal Chemistry, vol. 19, no. 33, pp. 5664–5676, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. K. Phillips, A. Luk, G. S. Soor, J. R. Abraham, S. Leong, and J. Butany, “Cocaine cardiotoxicity: a review of the pathophysiology, pathology, and treatment options,” American Journal of Cardiovascular Drugs, vol. 9, no. 3, pp. 177–196, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. A. Sarkar, A. Pande, G. S. Naveen Chandra, and I. Ahmed, “Acute myocardial infarction in a young cocaine addict with normal coronaries: time to raise awareness among emergency physicians,” Indian Journal of Critical Care Medicine, vol. 17, no. 1, pp. 56–58, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. D. M. Wood, P. I. Dargan, and R. S. Hoffman, “Management of cocaine-induced cardiac arrhythmias due to cardiac ion channel dysfunction,” Clinical Toxicology, vol. 47, no. 1, pp. 14–23, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. D. J. Heal, J. Gosden, and S. L. Smith, “Dopamine reuptake transporter (DAT) “inverse agonism”—a novel hypothesis to explain the enigmatic pharmacology of cocaine,” Neuropharmacology, vol. 87, pp. 19–40, 2014. View at Publisher · View at Google Scholar · View at Scopus
  37. M. W. Fischman, C. R. Schuster, L. Resnekov et al., “Cardiovascular and subjective effects of intravenous cocaine administration in humans,” Archives of General Psychiatry, vol. 33, no. 8, pp. 983–989, 1976. View at Publisher · View at Google Scholar · View at Scopus
  38. W. Vongpatanasin, Y. Mansour, B. Chavoshan, D. Arbique, and R. G. Victor, “Cocaine stimulates the human cardiovascular system via a central mechanism of action,” Circulation, vol. 100, no. 5, pp. 497–502, 1999. View at Publisher · View at Google Scholar · View at Scopus
  39. W. Kerns II, L. Garvey, and J. Owens, “Cocaine-induced wide complex dysrhythmia,” The Journal of Emergency Medicine, vol. 15, no. 3, pp. 321–329, 1997. View at Publisher · View at Google Scholar · View at Scopus
  40. V. M. Costa, F. Carvalho, M. L. Bastos, R. A. Carvalho, M. Carvalho, and F. Remião, “Contribution of catecholamine reactive intermediates and oxidative stress to the pathologic features of heart diseases,” Current Medicinal Chemistry, vol. 18, no. 15, pp. 2272–2314, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. B. J. Borkowski, Y. Cheema, A. U. Shahbaz, S. K. Bhattacharya, and K. T. Weber, “Cation dyshomeostasis and cardiomyocyte necrosis: the Fleckenstein hypothesis revisited,” European Heart Journal, vol. 32, no. 15, pp. 1846–1853, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. M. J. Brown, D. C. Brown, and M. B. Murphy, “Hypokalemia from beta2-receptor stimulation by circulating epinephrine,” The New England Journal of Medicine, vol. 309, no. 23, pp. 1414–1419, 1983. View at Publisher · View at Google Scholar · View at Scopus
  43. K. Ueshima, H. Tachibana, T. Suzuki, and K. Hiramori, “Factors affecting the blood concentration of ionized magnesium in patients in the acute phase of myocardial infarction,” Heart and Vessels, vol. 19, no. 6, pp. 267–270, 2004. View at Publisher · View at Google Scholar · View at Scopus
  44. A. A. McDonough, J. B. Velotta, R. H. G. Schwinger, K. D. Philipson, and R. A. Farley, “The cardiac sodium pump: structure and function,” Basic Research in Cardiology, vol. 97, supplement 1, pp. 19–24, 2002. View at Google Scholar · View at Scopus
  45. M. U. Khan, B. O. Komolafe, and K. T. Weber, “Cation interdependency in acute stressor states,” The American Journal of the Medical Sciences, vol. 345, no. 5, pp. 401–404, 2013. View at Publisher · View at Google Scholar · View at Scopus
  46. A. Fleckenstein, J. Janke, H. J. Döring, and O. Leder, “Myocardial fiber necrosis due to intracellular Ca overload—a new principle in cardiac pathophysiology,” Recent Advances in Studies on Cardiac Structure and Metabolism, vol. 4, pp. 563–580, 1974. View at Google Scholar · View at Scopus
  47. D. M. Bers, “Cardiac excitation-contraction coupling,” Nature, vol. 415, no. 6868, pp. 198–205, 2002. View at Publisher · View at Google Scholar · View at Scopus
  48. R.-P. Xiao, H. Cheng, Y.-Y. Zhou, M. Kuschel, and E. G. Lakatta, “Recent advances in cardiac β2-adrenergic signal transduction,” Circulation Research, vol. 85, no. 11, pp. 1092–1100, 1999. View at Publisher · View at Google Scholar · View at Scopus
  49. S. Orrenius, V. Gogvadze, and B. Zhivotovsky, “Calcium and mitochondria in the regulation of cell death,” Biochemical and Biophysical Research Communications, vol. 460, no. 1, pp. 72–81, 2015. View at Publisher · View at Google Scholar
  50. J. J. Lemasters, T. Qian, C. A. Bradham et al., “Mitochondrial dysfunction in the pathogenesis of necrotic and apoptotic cell death,” Journal of Bioenergetics and Biomembranes, vol. 31, no. 4, pp. 305–319, 1999. View at Publisher · View at Google Scholar · View at Scopus
  51. A. I. Tarasov, E. J. Griffiths, and G. A. Rutter, “Regulation of ATP production by mitochondrial Ca2+,” Cell Calcium, vol. 52, no. 1, pp. 28–35, 2012. View at Publisher · View at Google Scholar · View at Scopus
  52. G. S. Behonick, M. J. Novak, E. W. Nealley, and S. I. Baskin, “Toxicology update: the cardiotoxicity of the oxidative stress metabolites of catecholamines (aminochromes),” Journal of Applied Toxicology, vol. 21, supplement 1, pp. S15–S22, 2001. View at Publisher · View at Google Scholar · View at Scopus
  53. N. S. Dhalla, A. Adameova, and M. Kaur, “Role of catecholamine oxidation in sudden cardiac death,” Fundamental & Clinical Pharmacology, vol. 24, no. 5, pp. 539–546, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. J. L. Rouleau, B. Pitt, N. S. Dhalla et al., “Prognostic importance of the oxidized product of catecholamines, adrenolutin, in patients with severe heart failure,” American Heart Journal, vol. 145, no. 5, pp. 926–932, 2003. View at Publisher · View at Google Scholar · View at Scopus
  55. D. Cerretani, V. Fineschi, S. Bello, I. Riezzo, E. Turillazzi, and M. Neri, “Role of oxidative stress in cocaine-induced cardiotoxicity and cocaine-related death,” Current Medicinal Chemistry, vol. 19, no. 33, pp. 5619–5623, 2012. View at Publisher · View at Google Scholar · View at Scopus
  56. V. M. Costa, F. Carvalho, J. A. Duarte, M. D. L. Bastos, and F. Remião, “The heart as a target for xenobiotic toxicity: the cardiac susceptibility to oxidative stress,” Chemical Research in Toxicology, vol. 26, no. 9, pp. 1285–1311, 2013. View at Publisher · View at Google Scholar · View at Scopus
  57. L. Xiao, D. R. Pimentel, J. Wang, K. Singh, W. S. Colucci, and D. B. Sawyer, “Role of reactive oxygen species and NAD(P)H oxidase in α1-adrenoceptor signaling in adult rat cardiac myocytes,” American Journal of Physiology—Cell Physiology, vol. 282, no. 4, pp. C926–C934, 2002. View at Publisher · View at Google Scholar · View at Scopus
  58. C. E. Murdoch, M. Zhang, A. C. Cave, and A. M. Shah, “NADPH oxidase-dependent redox signalling in cardiac hypertrophy, remodelling and failure,” Cardiovascular Research, vol. 71, no. 2, pp. 208–215, 2006. View at Publisher · View at Google Scholar · View at Scopus
  59. F. Moritz, C. Monteil, M. Isabelle et al., “Role of reactive oxygen species in cocaine-induced cardiac dysfunction,” Cardiovascular Research, vol. 59, no. 4, pp. 834–843, 2003. View at Publisher · View at Google Scholar · View at Scopus
  60. T. Ago, J. Kuroda, M. Kamouchi, J. Sadoshima, and T. Kitazono, “Pathophysiological roles of NADPH oxidase/Nox family proteins in the vascular system—review and perspective,” Circulation Journal, vol. 75, no. 8, pp. 1791–1800, 2011. View at Publisher · View at Google Scholar · View at Scopus
  61. K. Bedard and K.-H. Krause, “The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology,” Physiological Reviews, vol. 87, no. 1, pp. 245–313, 2007. View at Publisher · View at Google Scholar · View at Scopus
  62. H. Sumimoto, “Structure, regulation and evolution of Nox-family NADPH oxidases that produce reactive oxygen species,” FEBS Journal, vol. 275, no. 13, pp. 3249–3277, 2008. View at Publisher · View at Google Scholar
  63. F. Xiong, D. Xiao, and L. Zhang, “Norepinephrine causes epigenetic repression of PKCε gene in rodent hearts by activating Nox1-dependent reactive oxygen species production,” The FASEB Journal, vol. 26, no. 7, pp. 2753–2763, 2012. View at Publisher · View at Google Scholar · View at Scopus
  64. M. Isabelle, A. Vergeade, F. Moritz et al., “NADPH oxidase inhibition prevents cocaine-induced up-regulation of xanthine oxidoreductase and cardiac dysfunction,” Journal of Molecular and Cellular Cardiology, vol. 42, no. 2, pp. 326–332, 2007. View at Publisher · View at Google Scholar · View at Scopus
  65. A. Vergeade, P. Mulder, C. Vendeville, R. Ventura-Clapier, C. Thuillez, and C. Monteil, “Xanthine oxidase contributes to mitochondrial ROS generation in an experimental model of cocaine-induced diastolic dysfunction,” Journal of Cardiovascular Pharmacology, vol. 60, no. 6, pp. 538–543, 2012. View at Publisher · View at Google Scholar · View at Scopus
  66. D. C. Andersson, J. Fauconnier, T. Yamada et al., “Mitochondrial production of reactive oxygen species contributes to the β-adrenergic stimulation of mouse cardiomycytes,” The Journal of Physiology, vol. 589, no. 7, pp. 1791–1801, 2011. View at Publisher · View at Google Scholar · View at Scopus
  67. A. Vergeade, P. Mulder, C. Vendeville-Dehaudt et al., “Mitochondrial impairment contributes to cocaine-induced cardiac dysfunction: prevention by the targeted antioxidant MitoQ,” Free Radical Biology and Medicine, vol. 49, no. 5, pp. 748–756, 2010. View at Publisher · View at Google Scholar · View at Scopus
  68. A. F. Branco, S. F. Sampaio, M. R. Wieckowski, V. A. Sardão, and P. J. Oliveira, “Mitochondrial disruption occurs downstream from β-adrenergic overactivation by isoproterenol in differentiated, but not undifferentiated H9c2 cardiomyoblasts: differential activation of stress and survival pathways,” International Journal of Biochemistry and Cell Biology, vol. 45, no. 11, pp. 2379–2391, 2013. View at Publisher · View at Google Scholar · View at Scopus
  69. S. Papa, “The NDUFS4 nuclear gene of complex I of mitochondria and the cAMP cascade,” Biochimica et Biophysica Acta—Bioenergetics, vol. 1555, no. 1–3, pp. 147–153, 2002. View at Publisher · View at Google Scholar · View at Scopus
  70. S. Nagasaka, H. Katoh, F. N. Chun et al., “Protein kinase A catalytic subunit alters cardiac mitochondrial redox state and membrane potential via the formation of reactive oxygen species,” Circulation Journal, vol. 71, no. 3, pp. 429–436, 2007. View at Publisher · View at Google Scholar · View at Scopus
  71. S. Srivastava, B. Chandrasekar, Y. Gu et al., “Downregulation of CuZn-superoxide dismutase contributes to β-adrenergic receptor-mediated oxidative stress in the heart,” Cardiovascular Research, vol. 74, no. 3, pp. 445–455, 2007. View at Publisher · View at Google Scholar · View at Scopus
  72. L. Lai, L. Yan, S. Gao et al., “Type 5 adenylyl cyclase increases oxidative stress by transcriptional regulation of manganese superoxide dismutase via the SIRT1/FoxO3a pathway,” Circulation, vol. 127, no. 16, pp. 1692–1701, 2013. View at Publisher · View at Google Scholar · View at Scopus
  73. A. Adameova, Y. Abdellatif, and N. S. Dhalla, “Role of the excessive amounts of circulating catecholamines and glucocorticoids in stress-induced heart disease,” Canadian Journal of Physiology and Pharmacology, vol. 87, no. 7, pp. 493–514, 2009. View at Publisher · View at Google Scholar · View at Scopus
  74. V. M. Costa, R. Silva, L. M. Ferreira et al., “Oxidation process of adrenaline in freshly isolated rat cardiomyocytes: formation of adrenochrome, quinoproteins, and GSH adduct,” Chemical Research in Toxicology, vol. 20, no. 8, pp. 1183–1191, 2007. View at Publisher · View at Google Scholar · View at Scopus
  75. M. Neri, D. Cerretani, A. I. Fiaschi et al., “Correlation between cardiac oxidative stress and myocardial pathology due to acute and chronic norepinephrine administration in rats,” Journal of Cellular and Molecular Medicine, vol. 11, no. 1, pp. 156–170, 2007. View at Publisher · View at Google Scholar · View at Scopus
  76. A. F. E. Rump, J. Schierholz, and W. Klaus, “Studies on the cardiotoxicity of noradrenaline in isolated rabbit hearts,” Arzneimittel-Forschung, vol. 52, no. 7, pp. 543–551, 2002. View at Google Scholar · View at Scopus
  77. P. Hašková, P. Kovaříková, L. Koubková, A. Vávrová, E. MacKová, and T. Šimůnek, “Iron chelation with salicylaldehyde isonicotinoyl hydrazone protects against catecholamine autoxidation and cardiotoxicity,” Free Radical Biology & Medicine, vol. 50, no. 4, pp. 537–549, 2011. View at Publisher · View at Google Scholar · View at Scopus
  78. M. S. Wolin and F. L. Belloni, “Superoxide anion selectively attenuates catecholamine-induced contractile tension in isolated rabbit aorta,” The American Journal of Physiology, vol. 249, no. 6, pp. H1127–H1133, 1985. View at Google Scholar · View at Scopus
  79. F. Remião, M. Carvalho, H. Carmo, F. Carvalho, and M. L. Bastos, “Cu2+-induced isoproterenol oxidation into isoprenochrome in adult rat calcium-tolerant cardiomyocytes,” Chemical Research in Toxicology, vol. 15, no. 6, pp. 861–869, 2002. View at Publisher · View at Google Scholar · View at Scopus
  80. P. Hašková, L. Koubková, A. Vávrová et al., “Comparison of various iron chelators used in clinical practice as protecting agents against catecholamine-induced oxidative injury and cardiotoxicity,” Toxicology, vol. 289, no. 2-3, pp. 122–131, 2011. View at Publisher · View at Google Scholar · View at Scopus
  81. K. P. Minneman, “α1-Adrenergic receptor subtypes, inositol phosphates, and sources of cell Ca2+,” Pharmacological Reviews, vol. 40, no. 2, pp. 87–119, 1988. View at Google Scholar · View at Scopus
  82. J. R. Docherty, “Subtypes of functional α1-adrenoceptor,” Cellular and Molecular Life Sciences, vol. 67, no. 3, pp. 405–417, 2010. View at Publisher · View at Google Scholar · View at Scopus
  83. D. M. Perez, “Structure-function of α1-adrenergic receptors,” Biochemical Pharmacology, vol. 73, no. 8, pp. 1051–1062, 2007. View at Publisher · View at Google Scholar · View at Scopus
  84. L. Pradhan, D. Mondal, S. Chandra, M. Ali, and K. C. Agrawal, “Molecular analysis of cocaine-induced endothelial dysfunction: role of endothelin-1 and nitric oxide,” Cardiovascular Toxicology, vol. 8, no. 4, pp. 161–171, 2008. View at Publisher · View at Google Scholar · View at Scopus
  85. E. P. Havranek, K. Nademanee, P. A. Grayburn, and E. J. Eichhorn, “Endothelium-dependent vasorelaxation is impaired in cocaine arteriopathy,” Journal of the American College of Cardiology, vol. 28, no. 5, pp. 1168–1174, 1996. View at Publisher · View at Google Scholar · View at Scopus
  86. G. I. Togna, M. Graziani, P. Russo, and L. Caprino, “Cocaine toxic effect on endothelium-dependent vasorelaxation: an in vitro study on rabbit aorta,” Toxicology Letters, vol. 123, no. 1, pp. 43–50, 2001. View at Publisher · View at Google Scholar · View at Scopus
  87. J. He, S. Yang, and L. Zhang, “Effects of cocaine on nitric oxide production in bovine coronary artery endothelial cells,” Journal of Pharmacology and Experimental Therapeutics, vol. 314, no. 3, pp. 980–986, 2005. View at Publisher · View at Google Scholar · View at Scopus
  88. C. G. Sáez, P. Olivares, J. Pallavicini et al., “Increased number of circulating endothelial cells and plasma markers of endothelial damage in chronic cocaine users,” Thrombosis Research, vol. 128, no. 4, pp. e18–e23, 2011. View at Publisher · View at Google Scholar · View at Scopus
  89. M. I. Mendoza-Baumgart, M. Pravetoni, and S. B. Sparber, “Inhibition of nitric oxide synthase enhances cocaine's developmental toxicity: vascular and CNS effects,” Neuropsychopharmacology, vol. 32, no. 4, pp. 940–945, 2007. View at Publisher · View at Google Scholar · View at Scopus
  90. D. Ramzy, V. Rao, L. C. Tumiati et al., “Elevated endothelin-1 levels impair nitric oxide homeostasis through a PKC-dependent pathway,” Circulation, vol. 114, no. 1, pp. I319–I326, 2006. View at Publisher · View at Google Scholar · View at Scopus
  91. R. López-Sepúlveda, M. Gómez-Guzmán, M. J. Zarzuelo et al., “Red wine polyphenols prevent endothelial dysfunction induced by endothelin-1 in rat aorta: role of NADPH oxidase,” Clinical Science, vol. 120, no. 8, pp. 321–333, 2011. View at Publisher · View at Google Scholar · View at Scopus
  92. S. Wedgwood and S. M. Black, “Endothelin-1 decreases endothelial NOS expression and activity through ETA receptor-mediated generation of hydrogen peroxide,” American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 288, no. 3, pp. L480–L487, 2005. View at Publisher · View at Google Scholar · View at Scopus
  93. U. Landmesser, B. Hornig, and H. Drexler, “Endothelial function: a critical determinant in atherosclerosis?” Circulation, vol. 109, supplement 1, no. 21, pp. 27–33, 2004. View at Publisher · View at Google Scholar · View at Scopus
  94. R. Patrizi, V. Pasceri, A. Sciahbasi, F. Summaria, G. M. C. Rosano, and E. Lioy, “Evidence of cocaine-related coronary atherosclerosis in young patients with myocardial infarction,” Journal of the American College of Cardiology, vol. 47, no. 10, pp. 2120–2122, 2006. View at Publisher · View at Google Scholar · View at Scopus
  95. M. R. Dashwood and J. C. S. Tsui, “Further evidence for a role of endothelin-1 (ET-1) in critical limb ischaemia,” Journal of Cell Communication and Signaling, vol. 5, no. 1, pp. 45–49, 2011. View at Publisher · View at Google Scholar · View at Scopus
  96. E. D. Flores, R. A. Lange, R. G. Cigarroa, and L. D. Hillis, “Effect of cocaine on coronary artery dimensions in atherosclerotic coronary artery disease: enhanced vasoconstriction at sites of significant stenoses,” Journal of the American College of Cardiology, vol. 16, no. 1, pp. 74–79, 1990. View at Publisher · View at Google Scholar · View at Scopus
  97. J. L. Cook and C. L. Randall, “Cocaine does not affect prostacyclin, thromboxane or prostaglandin E production in human umbilical veins,” Drug and Alcohol Dependence, vol. 41, no. 2, pp. 113–118, 1996. View at Publisher · View at Google Scholar · View at Scopus
  98. D. S. Mastrogiannis and W. F. O'Brien, “Cocaine affects prostaglandin production in human umbilical cord cell cultures,” The Journal of Maternal-Fetal & Neonatal Medicine, vol. 14, no. 4, pp. 261–266, 2003. View at Publisher · View at Google Scholar · View at Scopus
  99. G. Togna, M. Graziani, C. Sorrentino, and L. Caprino, “Prostanoid production in the presence of platelet activation in hypoxic cocaine-treated rats,” Haemostasis, vol. 26, no. 6, pp. 311–318, 1996. View at Google Scholar · View at Scopus
  100. M. M. Hynynen and R. A. Khalil, “The vascular endothelin system in hypertension—recent patents and discoveries,” Recent Patents on Cardiovascular Drug Discovery, vol. 1, no. 1, pp. 95–108, 2006. View at Publisher · View at Google Scholar · View at Scopus
  101. W. E. Hobbs, E. E. Moore, R. A. Penkala, D. D. Bolgiano, and J. A. López, “Cocaine and specific cocaine metabolites induce von Willebrand factor release from endothelial cells in a tissue-specific manner,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 33, no. 6, pp. 1230–1237, 2013. View at Publisher · View at Google Scholar · View at Scopus
  102. G. Togna, E. Tempesta, A. R. Togna, N. Dolci, B. Cebo, and L. Caprino, “Platelet responsiveness and biosynthesis of thromboxane and prostacyclin in response to in vitro cocaine treatment,” Haemostasis, vol. 15, no. 2, pp. 100–107, 1985. View at Google Scholar · View at Scopus
  103. A. D. Kugelmass, R. P. Shannon, E. L. Yeo, and J. A. Ware, “Intravenous cocaine induces platelet activation in the conscious dog,” Circulation, vol. 91, no. 5, pp. 1336–1340, 1995. View at Publisher · View at Google Scholar · View at Scopus
  104. L. K. Jennings, M. M. White, C. M. Sauer, A. M. Mauer, and J. T. Robertson, “Cocaine-induced platelet defects,” Stroke, vol. 24, no. 9, pp. 1352–1359, 1993. View at Publisher · View at Google Scholar · View at Scopus
  105. S. H. Rezkalla, J. J. Mazza, R. A. Kloner, V. Tillema, and S.-H. Chang, “Effects of cocaine on human platelets in healthy subjects,” The American Journal of Cardiology, vol. 72, no. 2, pp. 243–246, 1993. View at Publisher · View at Google Scholar · View at Scopus
  106. A. D. Kugelmass, A. Oda, K. Monahan, C. Cabral, and J. A. Ware, “Activation of human platelets by cocaine,” Circulation, vol. 88, no. 3, pp. 876–883, 1993. View at Publisher · View at Google Scholar · View at Scopus
  107. H. M. Rinder, K. A. Ault, P. I. Jatlow, T. R. Kosten, and B. R. Smith, “Platelet α-granule release in cocaine users,” Circulation, vol. 90, no. 3, pp. 1162–1167, 1994. View at Publisher · View at Google Scholar · View at Scopus
  108. C. M. Heesch, C. R. Wilhelm, J. Ristich, J. Adnane, F. A. Bontempo, and W. R. Wagner, “Cocaine activates platelets and increases the formation of circulating platelet containing microaggregates in humans,” Heart, vol. 83, no. 6, pp. 688–695, 2000. View at Publisher · View at Google Scholar · View at Scopus
  109. J. Pereira, C. G. Sáez, J. Pallavicini et al., “Platelet activation in chronic cocaine users: effect of short term abstinence,” Platelets, vol. 22, no. 8, pp. 596–601, 2011. View at Publisher · View at Google Scholar · View at Scopus
  110. M. Kiebala, M. V. Singh, M. S. Piepenbrink, X. Qiu, J. J. Kobie, and S. B. Maggirwar, “Platelet activation in human immunodeficiency virus type-1 patients is not altered with cocaine abuse,” PLoS ONE, vol. 10, no. 6, Article ID e0130061, 2015. View at Publisher · View at Google Scholar
  111. C. Aoui, A. Prigent, C. Sut et al., “The signaling role of cd40 ligand in platelet biology and in platelet component transfusion,” International Journal of Molecular Sciences, vol. 15, no. 12, pp. 22342–22364, 2014. View at Publisher · View at Google Scholar · View at Scopus
  112. J. S. McNally, M. E. Davis, D. P. Giddens et al., “Role of xanthine oxidoreductase and NAD(P)H oxidase in endothelial superoxide production in response to oscillatory shear stress,” The American Journal of Physiology—Heart and Circulatory Physiology, vol. 285, no. 6, pp. H2290–H2297, 2003. View at Publisher · View at Google Scholar · View at Scopus
  113. U. Landmesser, S. Dikalov, S. R. Price et al., “Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension,” The Journal of Clinical Investigation, vol. 111, no. 8, pp. 1201–1209, 2003. View at Publisher · View at Google Scholar · View at Scopus
  114. J. F. Turrens, “Mitochondrial formation of reactive oxygen species,” Journal of Physiology, vol. 552, no. 2, pp. 335–344, 2003. View at Publisher · View at Google Scholar · View at Scopus
  115. Z. Q. Zhao, “Mitochondrial formation of reactive oxygen species. Oxidative stress-elicited myocardial apoptosis during reperfusion,” Current Opinion in Pharmacology, vol. 4, no. 2, pp. 159–165, 2004. View at Google Scholar
  116. V. Darley-Usmar, “The powerhouse takes control of the cell; the role of mitochondria in signal transduction,” Free Radical Biology and Medicine, vol. 37, no. 6, pp. 753–754, 2004. View at Publisher · View at Google Scholar · View at Scopus
  117. N. Kaludercic, J. Mialet-Perez, N. Paolocci, A. Parini, and F. Di Lisa, “Monoamine oxidases as sources of oxidants in the heart,” Journal of Molecular and Cellular Cardiology, vol. 73, pp. 34–42, 2014. View at Publisher · View at Google Scholar · View at Scopus
  118. F. Carvalho, J. Duarte, M. Neuparth et al., “Hydrogen peroxide production in mouse tissues after acute d-amphetamine administration. Influence of monoamine oxidase inhibition,” Archives of Toxicology, vol. 75, no. 8, pp. 465–469, 2001. View at Publisher · View at Google Scholar · View at Scopus
  119. P. Dalvi, K. Wang, J. Mermis et al., “HIV-1/Cocaine induced oxidative stress disrupts tight junction protein-1 in human pulmonary microvascular endothelial cells: Role of RAS/ERK1/2 pathway,” PLoS ONE, vol. 9, no. 1, Article ID 0085246, 2014. View at Publisher · View at Google Scholar · View at Scopus
  120. H. Cai, “Hydrogen peroxide regulation of endothelial function: origins, mechanisms, and consequences,” Cardiovascular Research, vol. 68, no. 1, pp. 26–36, 2005. View at Publisher · View at Google Scholar · View at Scopus
  121. D. B. Zorov, M. Juhaszova, and S. J. Sollott, “Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release,” Physiological Reviews, vol. 94, no. 3, pp. 909–950, 2014. View at Publisher · View at Google Scholar · View at Scopus
  122. M. A. Aon, S. Cortassa, F. G. Akar, and B. O'Rourke, “Mitochondrial criticality: a new concept at the turning point of life or death,” Biochimica et Biophysica Acta, vol. 1762, no. 2, pp. 232–240, 2006. View at Publisher · View at Google Scholar · View at Scopus
  123. D. B. Zorov, C. R. Filburn, L.-O. Klotz, J. L. Zweier, and S. J. Sollott, “Reactive oxygen species (ROS)-induced ROS release: a new phenomenon accompanying induction of the mitochondrial permeability transition in cardiac myocytes,” The Journal of Experimental Medicine, vol. 192, no. 7, pp. 1001–1014, 2000. View at Publisher · View at Google Scholar · View at Scopus
  124. B. Lassègue, A. San Martín, and K. K. Griendling, “Biochemistry, physiology, and pathophysiology of NADPH oxidases in the cardiovascular system,” Circulation Research, vol. 110, no. 10, pp. 1364–1390, 2012. View at Publisher · View at Google Scholar · View at Scopus
  125. M. A. Kluge, J. L. Fetterman, and J. A. Vita, “Mitochondria and endothelial function,” Circulation Research, vol. 112, no. 8, pp. 1171–1188, 2013. View at Publisher · View at Google Scholar · View at Scopus
  126. L. S. Yoshida and S. Tsunawaki, “Expression of NADPH oxidases and enhanced H2O2-generating activity in human coronary artery endothelial cells upon induction with tumor necrosis factor-α,” International Immunopharmacology, vol. 8, no. 10, pp. 1377–1385, 2008. View at Publisher · View at Google Scholar · View at Scopus
  127. Y. W. Lee, B. Hennig, M. Fiala, K. S. Kim, and M. Toborek, “Cocaine activates redox-regulated transcription factors and induces TNF-α expression in human brain endothelial cells,” Brain Research, vol. 920, no. 1-2, pp. 125–133, 2001. View at Publisher · View at Google Scholar · View at Scopus
  128. F. Balaguer, J. Fernández, M. Lozano, R. Miquel, and A. Mas, “Cocaine-induced acute hepatitis and thrombotic microangiopathy,” The Journal of the American Medical Association, vol. 293, no. 7, pp. 797–798, 2005. View at Publisher · View at Google Scholar · View at Scopus
  129. M. J. Pérez, D. M. García, I. S. Leiva, and R. O. García, “Cocaine-induced hepatotoxicity,” Medicina Clinica, vol. 130, no. 7, article 279, 2008. View at Publisher · View at Google Scholar · View at Scopus
  130. L. E. Perino, G. H. Warren, and J. S. Levine, “Cocaine-induced hepatotoxicity in humans,” Gastroenterology, vol. 93, no. 1, pp. 176–180, 1987. View at Google Scholar · View at Scopus
  131. I. R. Wanless, S. Dore, N. Gopinath et al., “Histopathology of cocaine hepatotoxicity. Report of four patients,” Gastroenterology, vol. 98, no. 2, pp. 497–501, 1990. View at Google Scholar · View at Scopus
  132. G. C. Kanel, W. Cassidy, L. Shuster, and T. B. Reynolds, “Cocaine-induced liver cell injury: comparison of morphological features in man and in experimental models,” Hepatology, vol. 11, no. 4, pp. 646–651, 1990. View at Publisher · View at Google Scholar · View at Scopus
  133. A. Payancé, B. Scotto, J.-M. Perarnau, A. de Muret, and Y. Bacq, “Severe chronic hepatitis secondary to prolonged use of ecstasy and cocaine,” Clinics and Research in Hepatology and Gastroenterology, vol. 37, no. 5, pp. 109–113, 2013. View at Publisher · View at Google Scholar · View at Scopus
  134. R. Kothur, F. Marsh Jr., and G. Posner, “Liver function tests in nonparenteral cocaine users,” Archives of Internal Medicine, vol. 151, no. 6, pp. 1126–1128, 1991. View at Publisher · View at Google Scholar · View at Scopus
  135. V. Vitcheva, “Cocaine toxicity and hepatic oxidative stress,” Current Medicinal Chemistry, vol. 19, no. 33, pp. 5677–5682, 2012. View at Publisher · View at Google Scholar · View at Scopus
  136. I. Riezzo, C. Fiore, D. De Carlo et al., “Side effects of cocaine abuse: multiorgan toxicity and pathological consequences,” Current Medicinal Chemistry, vol. 19, no. 33, pp. 5624–5646, 2012. View at Publisher · View at Google Scholar · View at Scopus
  137. H. K. Watanabe, B. Hoskins, and I. K. Ho, “Sensitivity difference to hepatotoxicity of cocaine in spontaneously hypertensive and Wistar Kyoto rats,” Alcohol and Drug Research, vol. 7, no. 5-6, pp. 363–370, 1987. View at Google Scholar · View at Scopus
  138. M. L. Thompson, L. Shuster, and K. Shaw, “Cocaine-induced hepatic necrosis in mice—the role of cocaine metabolism,” Biochemical Pharmacology, vol. 28, no. 15, pp. 2389–2395, 1979. View at Publisher · View at Google Scholar · View at Scopus
  139. F. M. Ndikum-Moffor, T. R. Schoeb, and S. M. Roberts, “Liver toxicity from norcocaine nitroxide, an N-oxidative metabolite of cocaine,” Journal of Pharmacology and Experimental Therapeutics, vol. 284, no. 1, pp. 413–419, 1998. View at Google Scholar · View at Scopus
  140. P. Kovacic, “Role of oxidative metabolites of cocaine in toxicity and addiction: oxidative stress and electron transfer,” Medical Hypotheses, vol. 64, no. 2, pp. 350–356, 2005. View at Publisher · View at Google Scholar · View at Scopus
  141. L. M. Bornheim, “Effect of cytochrome P450 inducers on cocaine-mediated hepatotoxicity,” Toxicology and Applied Pharmacology, vol. 150, no. 1, pp. 158–165, 1998. View at Publisher · View at Google Scholar · View at Scopus
  142. K. Aoki, M. Takimoto, H. Ota, and T. Yoshida, “Participation of CYP2A in cocaine-induced hepatotoxicity in female mice,” Pharmacology & Toxicology, vol. 87, no. 1, pp. 26–32, 2000. View at Publisher · View at Google Scholar · View at Scopus
  143. S. Z. Mehanny and M. S. Abdel-Rahman, “Cocaine hepatotoxicity in mice: histologic and enzymatic studies,” Toxicologic Pathology, vol. 19, no. 1, pp. 24–29, 1991. View at Google Scholar · View at Scopus
  144. M. A. Evans and R. D. Harbison, “Cocaine-induced hepatotoxicity in mice,” Toxicology and Applied Pharmacology, vol. 45, no. 3, pp. 739–754, 1978. View at Publisher · View at Google Scholar · View at Scopus
  145. R. Labib, M. S. Abdel-Rahman, and R. Turkall, “N-acetylcysteine pretreatment decreases cocaine and endotoxin-induced hepatotoxicity,” Journal of Toxicology and Environmental Health, vol. 66, no. 3, pp. 223–239, 2003. View at Publisher · View at Google Scholar · View at Scopus
  146. R. Labib, R. Turkall, and M. S. Abdel-Rahman, “Endotoxin potentiates cocaine-mediated hepatotoxicity by nitric oxide and reactive oxygen species,” International Journal of Toxicology, vol. 22, no. 4, pp. 305–316, 2003. View at Publisher · View at Google Scholar · View at Scopus
  147. U. A. Boelsterli and C. Goldlin, “Biomechanisms of cocaine-induced hepatocyte injury mediated by the formation of reactive metabolites,” Archives of Toxicology, vol. 65, no. 5, pp. 351–360, 1991. View at Publisher · View at Google Scholar · View at Scopus
  148. A. Masini, D. Gallesi, F. Giovannini, T. Trenti, and D. Ceccarelli, “Membrane potential of hepatic mitochondria after acute cocaine administration in rats—the role of mitochondrial reduced glutathione,” Hepatology, vol. 25, no. 2, pp. 385–390, 1997. View at Google Scholar · View at Scopus
  149. B. G. Devi and A. W. K. Chan, “Impairment of mitochondrial respiration and electron transport chain enzymes during cocaine-induced hepatic injury,” Life Sciences, vol. 60, no. 11, pp. 849–855, 1997. View at Publisher · View at Google Scholar · View at Scopus
  150. F. Boess, F. M. Ndikum-Moffor, U. A. Boelsterli, and S. M. Roberts, “Effects of cocaine and its oxidative metabolites on mitochondrial respiration and generation of reactive oxygen species,” Biochemical Pharmacology, vol. 60, no. 5, pp. 615–623, 2000. View at Publisher · View at Google Scholar · View at Scopus
  151. D. A. Donnelly, C. S. Boyer, D. R. Petersen, and D. Ross, “Cocaine-induced biochemical changes and cytotoxicity in hepatocytes isolated from both mice and rats,” Chemico-Biological Interactions, vol. 67, no. 1-2, pp. 95–104, 1988. View at Publisher · View at Google Scholar · View at Scopus
  152. C. R. Göldlin and U. A. Boelsterli, “Reactive oxygen species and non-peroxidative mechanisms of cocaine-induced cytotoxicity in rat hepatocyte cultures,” Toxicology, vol. 69, no. 1, pp. 79–91, 1991. View at Publisher · View at Google Scholar · View at Scopus
  153. S. Connors, D. R. Rankin, A. J. Gandolfi, C. L. Krumdieck, L. J. Koep, and K. Brendel, “Cocaine hepatotoxicity in cultured liver slices: a species comparison,” Toxicology, vol. 61, no. 2, pp. 171–183, 1990. View at Publisher · View at Google Scholar · View at Scopus
  154. C. Göldlin and U. A. Boelsterli, “Dissociation of covalent protein adduct formation from oxidative injury in cultured hepatocytes exposed to cocaine,” Xenobiotica, vol. 24, no. 3, pp. 251–264, 1994. View at Publisher · View at Google Scholar · View at Scopus
  155. C. Díez-Fernández, A. Zaragoza, A. M. Alvarez, and M. Cascales, “Cocaine cytotoxicity in hepatocyte cultures from phenobarbital-induced rats: involvement of reactive oxygen species and expression of antioxidant defense systems,” Biochemical Pharmacology, vol. 58, no. 5, pp. 797–805, 1999. View at Publisher · View at Google Scholar · View at Scopus
  156. A. Zaragoza, C. Díez-Fernández, A. M. Alvarez, D. Andrés, and M. Cascales, “Effect of N-acetylcysteine and deferoxamine on endogenous antioxidant defense system gene expression in a rat hepatocyte model of cocaine cytotoxicity,” Biochimica et Biophysica Acta, vol. 1496, no. 2-3, pp. 183–195, 2000. View at Publisher · View at Google Scholar · View at Scopus
  157. O. Dean, F. Giorlando, and M. Berk, “N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action,” Journal of Psychiatry and Neuroscience, vol. 36, no. 2, pp. 78–86, 2011. View at Publisher · View at Google Scholar · View at Scopus
  158. D. Deepmala, J. Slattery, N. Kumar et al., “Clinical trials of N-acetylcysteine in psychiatry and neurology: a systematic review,” Neuroscience & Biobehavioral Reviews, vol. 55, pp. 294–321, 2015. View at Publisher · View at Google Scholar
  159. E. A. McClure, C. D. Gipson, R. J. Malcolm, P. W. Kalivas, and K. M. Gray, “Potential role of N-acetylcysteine in the management of substance use disorders,” CNS Drugs, vol. 28, no. 2, pp. 95–106, 2014. View at Publisher · View at Google Scholar · View at Scopus
  160. M. Berk, G. S. Malhi, L. J. Gray, and O. M. Dean, “The promise of N-acetylcysteine in neuropsychiatry,” Trends in Pharmacological Sciences, vol. 34, no. 3, pp. 167–177, 2013. View at Publisher · View at Google Scholar · View at Scopus
  161. S. D. LaRowe, P. W. Kalivas, J. S. Nicholas, P. K. Randall, P. N. Mardikian, and R. J. Malcolm, “A double-blind placebo-controlled trial of N-acetylcysteine in the treatment of cocaine dependence,” The American Journal on Addictions, vol. 22, no. 5, pp. 443–452, 2013. View at Publisher · View at Google Scholar · View at Scopus
  162. D. A. Baker, K. McFarland, R. W. Lake et al., “Neuroadaptations in cystine-glutamate exchange underlie cocaine relapse,” Nature Neuroscience, vol. 6, no. 7, pp. 743–749, 2003. View at Publisher · View at Google Scholar · View at Scopus
  163. E. Asevedo, A. C. Mendes, M. Berk, and E. Brietzke, “Systematic review of N-acetylcysteine in the treatment of addictions,” Revista Brasileira de Psiquiatria, vol. 36, no. 2, pp. 168–175, 2014. View at Publisher · View at Google Scholar · View at Scopus
  164. A. Gillissen, B. Schärling, M. Jaworska, A. Bartling, K. Rasche, and G. Schultze-Werninghaus, “Oxidant scavenger function of ambroxol in vitro: a comparison with N-acetylcysteine,” Research in Experimental Medicine, vol. 196, no. 6, pp. 389–398, 1997. View at Publisher · View at Google Scholar · View at Scopus
  165. L. Zhang, Z. Zhu, J. Liu, Z. Zhu, and Z. Hu, “Protective effect of N-acetylcysteine (NAC) on renal ischemia/reperfusion injury through Nrf2 signaling pathway,” Journal of Receptors and Signal Transduction, vol. 34, no. 5, pp. 396–400, 2014. View at Publisher · View at Google Scholar · View at Scopus
  166. J. L. Lim, M. M. M. Wilhelmus, H. E. de Vries, B. Drukarch, J. J. M. Hoozemans, and J. van Horssen, “Antioxidative defense mechanisms controlled by Nrf2: state-of-the-art and clinical perspectives in neurodegenerative diseases,” Archives of Toxicology, vol. 88, no. 10, pp. 1773–1786, 2014. View at Publisher · View at Google Scholar · View at Scopus
  167. G. R. Buettner, “Superoxide dismutase in redox biology: the roles of superoxide and hydrogen peroxide,” Anti-Cancer Agents in Medicinal Chemistry, vol. 11, no. 4, pp. 341–346, 2011. View at Publisher · View at Google Scholar · View at Scopus
  168. D. Salvemini, D. P. Riley, and S. Cuzzocrea, “SOD mimetics are coming of age,” Nature Reviews Drug Discovery, vol. 1, no. 5, pp. 367–374, 2002. View at Publisher · View at Google Scholar · View at Scopus
  169. J. B. de Haan and M. E. Cooper, “Targeted antioxidant therapies in hyperglycemia-mediated endothelial dysfunction,” Frontiers in Bioscience: Scholar, vol. 3, no. 2, pp. 709–729, 2011. View at Publisher · View at Google Scholar · View at Scopus
  170. R. A. Floyd, R. D. Kopke, C.-H. Choi, S. B. Foster, S. Doblas, and R. A. Towner, “Nitrones as therapeutics,” Free Radical Biology & Medicine, vol. 45, no. 10, pp. 1361–1374, 2008. View at Publisher · View at Google Scholar · View at Scopus
  171. E. D. Hall, “Antioxidant therapies for acute spinal cord injury,” Neurotherapeutics, vol. 8, no. 2, pp. 152–167, 2011. View at Publisher · View at Google Scholar · View at Scopus
  172. R. Numa, R. Kohen, T. Poltyrev, and R. Yaka, “Tempol diminishes cocaine-induced oxidative damage and attenuates the development and expression of behavioral sensitization,” Neuroscience, vol. 155, no. 3, pp. 649–658, 2008. View at Publisher · View at Google Scholar · View at Scopus
  173. E. J. Jang, Y. H. Ryu, B. H. Lee et al., “Involvement of reactive oxygen species in cocaine-taking behaviors in rats,” Addiction Biology, vol. 15, no. 4, pp. 663–675, 2015. View at Google Scholar
  174. J. Tinkel, H. Hassanain, and S. J. Khouri, “Cardiovascular antioxidant therapy: a review of supplements, pharmacotherapies, and mechanisms,” Cardiology in Review, vol. 20, no. 2, pp. 77–83, 2012. View at Publisher · View at Google Scholar · View at Scopus
  175. L. Rochette, S. Ghibu, C. Richard, M. Zeller, Y. Cottin, and C. Vergely, “Direct and indirect antioxidant properties of α-lipoic acid and therapeutic potential,” Molecular Nutrition and Food Research, vol. 57, no. 1, pp. 114–125, 2013. View at Publisher · View at Google Scholar · View at Scopus
  176. S. Sorce, K.-H. Krause, and V. Jaquet, “Targeting NOX enzymes in the central nervous system: therapeutic opportunities,” Cellular and Molecular Life Sciences, vol. 69, no. 14, pp. 2387–2407, 2012. View at Publisher · View at Google Scholar · View at Scopus
  177. T. Kahles and R. P. Brandes, “NADPH oxidases as therapeutic targets in ischemic stroke,” Cellular and Molecular Life Sciences, vol. 69, no. 14, pp. 2345–2363, 2012. View at Publisher · View at Google Scholar · View at Scopus
  178. A. Schramm, P. Matusik, G. Osmenda, and T. J. Guzik, “Targeting NADPH oxidases in vascular pharmacology,” Vascular Pharmacology, vol. 56, no. 5-6, pp. 216–231, 2012. View at Publisher · View at Google Scholar · View at Scopus
  179. L. Fan, D. Sawbridge, V. George et al., “Chronic cocaine-induced cardiac oxidative stress and mitogen-activated protein kinase activation: the role of Nox2 oxidase,” Journal of Pharmacology and Experimental Therapeutics, vol. 328, no. 1, pp. 99–106, 2009. View at Publisher · View at Google Scholar · View at Scopus
  180. P. Pacher, A. Nivorozhkin, and C. Szabó, “Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol,” Pharmacological Reviews, vol. 58, no. 1, pp. 87–114, 2006. View at Publisher · View at Google Scholar · View at Scopus
  181. D. M. Small, J. S. Coombes, N. Bennett, D. W. Johnson, and G. C. Gobe, “Oxidative stress, anti-oxidant therapies and chronic kidney disease,” Nephrology, vol. 17, no. 4, pp. 311–321, 2012. View at Publisher · View at Google Scholar · View at Scopus
  182. W. Doehner and U. Landmesser, “Xanthine oxidase and uric acid in cardiovascular disease: clinical impact and therapeutic options,” Seminars in Nephrology, vol. 31, no. 5, pp. 433–440, 2011. View at Publisher · View at Google Scholar · View at Scopus
  183. K. Aoki, M. Ohmori, M. Takimoto, H. Ota, and T. Yoshida, “Cocaine-induced liver injury in mice is mediated by nitric oxide and reactive oxygen species,” European Journal of Pharmacology, vol. 336, no. 1, pp. 43–49, 1997. View at Publisher · View at Google Scholar · View at Scopus
  184. R. A. J. Smith, R. C. Hartley, H. M. Cochemé, and M. P. Murphy, “Mitochondrial pharmacology,” Trends in Pharmacological Sciences, vol. 33, no. 6, pp. 341–352, 2012. View at Publisher · View at Google Scholar · View at Scopus
  185. R. A. J. Smith and M. P. Murphy, “Mitochondria-targeted antioxidants as therapies,” Discovery medicine, vol. 11, no. 57, pp. 106–114, 2011. View at Google Scholar · View at Scopus
  186. H. H. Szeto, “Cell-permeable, mitochondrial-targeted, peptide antioxidants,” The AAPS Journal, vol. 8, no. 2, pp. E277–E283, 2006. View at Publisher · View at Google Scholar · View at Scopus
  187. A. Sadakierska-Chudy, M. Frankowska, and M. Filip, “Mitoepigenetics and drug addiction,” Pharmacology & Therapeutics, vol. 144, no. 2, pp. 226–233, 2014. View at Publisher · View at Google Scholar · View at Scopus
  188. A. Zaragoza, C. Díez-Fernández, A. M. Alvarez, D. Andrés, and M. Cascales, “Mitochondrial involvement in cocaine-treated rat hepatocytes: Effect of N-acetylcysteine and deferoxamine,” British Journal of Pharmacology, vol. 132, no. 5, pp. 1063–1070, 2001. View at Publisher · View at Google Scholar · View at Scopus
  189. F. Moritz, C. Monteil, M. Isabelle et al., “Selenium diet-supplementation improves cocaine-induced myocardial oxidative stress and prevents cardiac dysfunction in rats,” Fundamental and Clinical Pharmacology, vol. 18, no. 4, pp. 431–436, 2004. View at Publisher · View at Google Scholar · View at Scopus
  190. I. Sinha-Hikim, R. Shen, I. Nzenwa, R. Gelfand, S. K. Mahata, and A. P. Sinha-Hikim, “Minocycline suppresses oxidative stress and attenuates fetal cardiac myocyte apoptosis triggered by in utero cocaine exposure,” Apoptosis, vol. 16, no. 6, pp. 563–573, 2011. View at Publisher · View at Google Scholar · View at Scopus
  191. J. M. Madeira, D. L. Gibson, W. F. Kean, and A. Klegeris, “The biological activity of auranofin: Implications for novel treatment of diseases,” Inflammopharmacology, vol. 20, no. 6, pp. 297–306, 2012. View at Publisher · View at Google Scholar · View at Scopus
  192. T. Ashino, J. Sugiuchi, J. Uehara et al., “Auranofin protects against cocaine-induced hepatic injury through induction of heme oxygenase-1,” Journal of Toxicological Sciences, vol. 36, no. 5, pp. 635–643, 2011. View at Publisher · View at Google Scholar · View at Scopus
  193. W. F. Kean, L. Hart, and W. W. Buchanan, “Auranofin,” British Journal of Rheumatology, vol. 36, no. 5, pp. 560–572, 1997. View at Publisher · View at Google Scholar · View at Scopus
  194. I. Tomomi, H. Tsutsui, S. Kinugawa, H. Utsumi, and A. Takeshita, “Amiodarone protects cardiac myocytes against oxidative injury by its free radical scavenging action,” Circulation, vol. 100, no. 7, pp. 690–692, 1999. View at Publisher · View at Google Scholar · View at Scopus
  195. C. R. DeWitt, N. Cleveland, R. C. Dart, and K. Heard, “The effect of amiodarone pretreatment on survival of mice with cocaine toxicity,” Journal of Medical Toxicology, vol. 1, no. 1, pp. 11–18, 2005. View at Publisher · View at Google Scholar · View at Scopus
  196. E. A. Kalimullah and S. M. Bryant, “Case files of the medical toxicology fellowship at the toxikon consortium in Chicago: cocaine-associated wide-complex dysrhythmias and cardiac arrest—treatment nuances and controversies,” Journal of Medical Toxicology, vol. 4, no. 4, pp. 277–283, 2008. View at Publisher · View at Google Scholar · View at Scopus
  197. D. A. G. Mickle and R. D. Weisel, “Future directions of vitamin E and its analogues in minimizing myocarcdial ischemia-reperfusion injury,” Canadian Journal of Cardiology, vol. 9, no. 1, pp. 89–93, 1993. View at Google Scholar · View at Scopus
  198. M. Y. Aksenov, M. V. Aksenova, A. Nath, P. D. Ray, C. F. Mactutus, and R. M. Booze, “Cocaine-mediated enhancement of Tat toxicity in rat hippocampal cell cultures: the role of oxidative stress and D1 dopamine receptor,” NeuroToxicology, vol. 27, no. 2, pp. 217–228, 2006. View at Publisher · View at Google Scholar · View at Scopus